Advaxis Stock Sale Draws $23M; Phase II Cancer Bids Under Way
Cancer immunotherapy gained another stamp of approval with the $23 million in gross proceeds raised by Advaxis Inc., which sold about 5.7 million shares plus warrants to buy about 2.8 million more, at a price of $4 per share and $0.01 per warrant.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter